Jan G. J. Van de Winkel, PhD | Source | President, Chief Executive Officer at Genmab
Jan G. J. Van de Winkel, PhD
President, Chief Executive Officer at Genmab
Link:
#AntibodyResearch#Antibodymedicines#CancerTreatment#InnovativeScience#HealthcareResearch#AntibodyTherapeutics#Genmab#President#CEO#ChiefExecutiveOfficer#BiotechInnovation#BiotechInnovations#Biotech#Biotechnology#TherapeuticAntibody#TherapeuticAntibodies#Patentapplications#ResearchAndDevelopment#Science
Bio
Edit
Dr. van de Winkel is the President and Chief Executive Officer at Genmab. He has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. Dr. van de Winkel is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.
Employment
Sign up to view all
-
Genmab (https://www.genmab.com/)
President, Chief Executive Officer
Media
Sign up to view all
-
Why Genmab is betting on AI to transform biopharma R&D
An exec at Genmab shares how strategic investments in AI accelerate research, inform clinical trials, and speed drug approvals.
Article
Recent Quotes
Sign up to view all
-
AI and access to digital information will play a big role in this.
